Collaboration and Licensing Agreements (Tables)

12 Months Ended

Dec. 31, 2022

Collaboration and Licensing Agreements

Schedule of revenue by licensees

The $164.6 million, $275.1 million, and $122.7 million of revenue recorded for the years ended December 31, 2022, 2021, and 2020, respectively, were earned principally from the following licensees (in millions):

	Year Ended December 31,
	2022		2021		2020
Aimmune	$	—	$	—	$	9.6
Alexion	29.4		22.2		26.2
Astellas	5.0		—		3.5
Genentech	—		2.5		3.5
Gilead	—		—		13.5
Janssen	7.0		113.8		—
MorphoSys	7.8		18.4		39.0
Novartis	—		43.1		—
Omeros	—		—		5.0
Vir	115.4		52.7		0.3
Viridian	—		7.5		6.0
Zenas	—		14.9		16.1
Total	$	164.6	$	275.1	$	122.7

Schedule of disaggregation of revenue

The table below summarizes the disaggregation of revenue recorded for the years ended December 31, 2022, 2021, and 2020 (in millions):

	Year Ended December 31,
	2022		2021		2020
Research collaboration	$	7.0	$	93.0	$	4.5
Milestone	5.5		21.0		50.2
Licensing	—		80.8		50.2
Royalties	152.1		80.3		17.8
Total	$	164.6	$	275.1	$	122.7